Tagged Articles

Bristol-Myers Squibb 30 articles

First three trials scheduled alleging Abilify causes compulsive behaviors

A random order for the first three cases to be tried in a multidistrict litigation blaming the antipsychotic drug Abilify for causing compulsive behaviors has been decided by U.S. District Judge M. Casey Rodgers. The cases are among about 750 pending in Florida federal court against Abilify makers Bristol-Myers Squibb and Otsuka Pharmaceutical. The cases are not intended to serve as true bellwethers because their selection was not based on an analysis of their characteristics or randomness. Instead, they were chosen for their convenience of being eligible for trial in the Northern District of Florida without a venue waiver. The ... Read More

NJ judge considers consolidating Abilify compulsion cases

Drug companies and dozens of people suing them over claims that the antipsychotic drug Abilify caused them to compulsively gamble or have sex, urged a New Jersey state court to grant multi-county litigation status to the pending cases, Law360 reported. The request was made to the New Jersey Supreme Court for cases pending in Bergen County Superior Court before Judge James J. DeLuca. Centralizing the cases would help cut the cost of litigating the cases of similar claims against Bristol-Myers Squibb Co. and Otsuka America Pharmaceutical Inc., brought by geographically dispersed plaintiffs. Abilify, which contains the active ingredient aripiprazole, was ... Read More

Manufacturing error leads to recall of generic version of Abilify

Nearly 68,000 bottles of a generic version of the antipsychotic medication Abilify are being recalled because of a manufacturing defect that rendered the tablets superpotent and likely unable to meet specifications throughout the product’s shelf life. The recall is listed as a Class III, and not considered to cause any serious adverse events. The recall is being initiated by Apotex Inc., and includes lot number MJ7746 with the expiration date of Apr. 4, 2017. The medication was distributed nationwide. Abilify was initially approved in 2002 as a treatment for schizophrenia. The indication of Abilify has since been expanded to include ... Read More

Bristol-Myers Squibb to pay states $19.5M over improper marketing of Abilify

Bristol-Myers Squibb will shell out $19.5 million to 42 states and Washington, D.C., to settle allegations that the drug maker improperly marketed its antipsychotic drug Abilify. Abilify, which contains the active ingredient aripiprazole, is currently approved by the Food and Drug Administration (FDA) to treat adults and adolescents with schizophrenia, adults and children with bipolar disorder, adults with major depressive disorder, and pediatric patients who exhibit irritability with autism. In 2006, the FDA warned that Abilify should not be used in elderly patients with dementia-related psychosis because the drug increased their risk of death. The states argued that Bristol-Myers Squibb ... Read More

Power cancer drugs linked to rare but serious heart problems

Breakthrough cancer treatments known as checkpoint inhibitors are offering hope to thousands of patients with life threatening forms of the disease. But a new study shows that some patients treated with this class of drugs have developed heart problems, which in some cases has been fatal. Checkpoint inhibitors, which include the brand names Yervoy (ipilimumab, Opdivo (nivolumab), Keytruda (pembrolizumab), and Tecentriq  (atezolizumab), are approved to treat six types of cancer. They are also sometimes combined with each other for added effectiveness. They work by prompting the immune system to kill off cancer cells. But in rare cases, the immune system ... Read More

Antidepressant Abilify linked to pathological gambling and hiccups

The antidepressant Abilify has been associated with new side effects – pathological gambling and hiccups. Abilify, known chemically as aripiprazole, is one of the most commonly prescribed treatments for mental disorders including depression, schizophrenia and bipolar disorder. It is made by Bristol-Myers Squibb and Otsuka Pharmaceutical Company, and generates billions in sales. Since Abilify was approved in November 2002, the drug has been associated with compulsive behavior side effects including pathological gambling, binge eating and hypersexuality. It is thought that these behaviors are triggered by the neurotransmitters dopamine and serotonin. Studies that linked Abilify to pathological gambling also found that gambling problems resolved after ... Read More

Lawsuits claim antidepressant Abilify causes compulsive gambling

Otsuka Pharmaceutical Company Ltd. And Bristol Myers Squibb Co. are facing two lawsuits involving claims that the drug companies failed to warn that their antidepressant Abilify could cause compulsive gambling or other compulsive behaviors. The lawsuits, filed in the U.S. District Court for the District of Minnesota and the U.S. District Court for the Southern District of New York, allege that plaintiffs began compulsively gambling shortly after taking Abilify, and then stopped soon after they discontinued use of the medication. Abilify is an atypical anti-psychotic drug that is used as an add-on treatment for adults with depression, and for children ... Read More

FDA approves new type of cancer drug to treat advanced melanoma

A new type of cancer drug has been approved by the Food and Drug Administration (FDA) to treat advanced or inoperable melanoma that no longer responds to other drugs. The drug, Keytruda (pembrolizumab), is made by Merck & Co., and is part of a new class of antibody-based drugs known as anti-PD-1. Keytruda works by activating a brake in the immune system to stop tumors from damaging the immune system. Keytruda is the first anti-PD-1 drug approved in the United States, however more cancer drugs from the class are expected to hit the market in the near future. Bristol-Myers Squibb’s ... Read More

Vials of blood thinner Coumadin recalled due to possible contamination

Six lots of the commonly prescribed blood thinner Coumadin (warfarin) are being recalled because visible particulate matter was found in some vials of the drug. If injected, particulate – whether of metallic or non-metallic cellulose matter – can cause serious and potentially fatal adverse reactions including embolization, as well as allergic reactions. Coumadin is a prescription medication used to treat blood clots and to lower the risk of blood clots forming in the body. It is available in both an oral and an injectable formulation. The injectable formulation is typically administered in a hospital setting by health care professionals to ... Read More

Personal injury lawsuits piling up against makers of blood thinner Plavix

Personal and financial injury lawsuits involving the blood thinner Plavix are piling up in New Jersey against the drug’s makers, with 73 currently in the multidistrict litigation with at least another 14 being considered for transfer. The lawsuits allege the drug companies falsely advertised the prescription anti-clotting medication as a gentler-than-aspirin treatment designed to prevent heart attacks and strokes even though they knew the drug increased the risk for heart attacks, strokes, internal bleeding and death. Plavix, also known as clopidogrel, is manufactured and sold by Bristol-Myers Squibb and Sanofi-Aventis, and is aided by McKesson Corporation. The drug was approved ... Read More